Regulatory and ClinicalDec 8, 2025 · 7:43pm ET
SNTISenti Biosciences Holdings, Inc. Common Stock
Senti Biosciences Announces Positive Clinical Data for SENTI-202 in R/R AML
Updated Phase 1 trial results show deep, durable remissions and favorable safety.
Regulatory and ClinicalDec 8, 2025 · 7:43pm ET
SNTISenti Biosciences Holdings, Inc. Common Stock+64.6%
Senti Biosciences Announces Positive Clinical Data for SENTI-202 in R/R AML